Alpa Laboratories Ltd (ALPA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 476646,
    "name": "Alpa Laboratorie",
    "stock_name": "Alpa Laboratorie",
    "full_name": "Alpa Laboratories Ltd",
    "name_url": "stocks-analysis/alpa-laboratorie",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "70.00",
    "chg": 2.22,
    "chgp": "3.28%",
    "dir": 1,
    "prev_price": "67.78",
    "mcapval": "143.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532878,
    "symbol": "ALPA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE385I01010",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "8.83 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/alpa-laboratorie-476646-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Alpa Laboratorie Sees Revision in Market Assessment Amid Challenging Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/alpa-laboratorie-downgraded-to-strong-sell-amid-deteriorating-fundamentals-3746489",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AlpaLaboratorie_mojoScore_3746489.png",
        "date": "2025-12-04 11:08:19",
        "description": "Alpa Laboratorie, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. Recent assessment changes highlight shifts across key performance parameters, signalling caution for investors amid subdued returns and operational difficulties."
      },
      {
        "title": "Why is Alpa Laboratorie falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-alpa-laboratorie-fallingrising-3742403",
        "imagepath": "",
        "date": "2025-12-03 00:39:18",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Alpa Laboratories’ latest price action stands out in comparison to broader market trends. Over the past week, the stock has appreciated by 12.61%, substantially outperforming the Sensex’s modest 0.65% gain during the same period. This recent rally contrasts with the stock’s longer-term performance, which has been subdued; it has declined by 5.40% over the last month and remains down 27.94% year-to-date, while the Sensex has advanced 8.96% in the same timeframe. Despite these setbacks, the stock’s three- and five-year returns remain robust, with gains of 59.83% and 137.23% respectively, comfortably outpacing the Sensex’s 35.42% and 90.82% returns over those periods.</p>\n<p>The intraday trading on 02-Dec was marked by considerable volati..."
      },
      {
        "title": "Alpa Laboratories Stock Falls to 52-Week Low of Rs.76.25",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alpa-laboratories-stock-falls-to-52-week-low-of-rs7625-3729263",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AlpaLaboratorie_priceRelatedfactors_3729263.png",
        "date": "2025-11-25 15:39:03",
        "description": "Alpa Laboratories has reached a new 52-week low, with its share price touching Rs.76.25 today. This marks a significant level for the pharmaceutical and biotechnology company amid a broader market environment where the Sensex is trading slightly lower."
      },
      {
        "title": "Alpa Laboratories Stock Falls to 52-Week Low of Rs.78.01",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alpa-laboratories-stock-falls-to-52-week-low-of-rs7801-3725390",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AlpaLaboratorie_priceRelatedfactors_3725390.png",
        "date": "2025-11-24 11:38:49",
        "description": "Alpa Laboratories has reached a new 52-week low of Rs.78.01, marking a significant decline amid broader market gains. The stock has underperformed its sector and key benchmarks, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology industry."
      },
      {
        "title": "Alpa Laboratories Falls to 52-Week Low of Rs.78.02 Amidst Market Rally",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alpa-laboratories-stock-falls-to-52-week-low-of-rs7802-3715529",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AlpaLaboratorie_priceRelatedfactors_3715529.png",
        "date": "2025-11-19 14:44:58",
        "description": "Alpa Laboratories, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.78.02 today, marking a significant decline amid a broadly positive market environment where the Sensex advanced by 0.64%."
      },
      {
        "title": "Alpa Laboratories Faces Financial Challenges Amidst Strong Sales Growth and Market Struggles",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alpa-laboratories-financial-trend-declines-from-flat-to-negative-amid-significant-profit-drop-3711822",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AlpaLaboratorie_fintrenddot_3711822.png",
        "date": "2025-11-18 12:00:52",
        "description": "Alpa Laboratories has reported a challenging financial period for the quarter ending September 2025, with a decline in overall performance metrics. Despite a 21.86% increase in net sales to Rs 85.29 crore, profit after tax fell significantly. The company faces concerns regarding key performance indicators and market performance relative to the Sensex."
      },
      {
        "title": "Alpa Laboratories Q2 FY26: Profit Plunges 98.57% as Operating Margins Turn Negative",
        "link": "https://www.marketsmojo.com/news/result-analysis/alpa-laboratories-q2-fy26-profit-plunges-9857-as-operating-margins-turn-negative-3718967",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AlpaLaboratorie_quaterlyResult_3718967.png",
        "date": "2025-11-18 09:59:32",
        "description": "Alpa Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer, reported deeply troubling results for Q2 FY26, with consolidated net profit collapsing 98.57% year-on-year to just ₹0.11 crores from ₹7.69 crores in the same quarter last year. The catastrophic decline reflects severe operational distress as the company's operating margins turned sharply negative for the first time in recent years, raising serious questions about business viability. The stock, currently trading at ₹80.85 with a market capitalisation of ₹168.00 crores, has declined 28.70% over the past year, significantly underperforming both the benchmark Sensex and the pharmaceuticals sector."
      },
      {
        "title": "Is Alpa Laboratorie overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-alpa-laboratorie-overvalued-or-undervalued-3709752",
        "imagepath": "",
        "date": "2025-11-18 08:20:36",
        "description": "As of 17 November 2025, the valuation grade for Alpa Laboratorie has moved from very attractive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE Ratio of 9.02, an EV to EBIT of -9.06, and an EV to EBITDA of -29.26, which suggest that the company's earnings and cash flows are under pressure.\n\nIn comparison to its peers, Alpa Laboratorie shows a stark contrast with Sun Pharma, which has a PE Ratio of 36.69 and an EV to EBITDA of 24.22, and Cipla, with a PE Ratio of 22.81 and an EV to EBITDA of 16.14. These comparisons highlight that Alpa Laboratorie is lagging behind its industry counterparts in terms of valuation metrics. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -33.37% compared to the Sensex's 8.72%, reinforcing the notion of its overvaluation...."
      },
      {
        "title": "How has been the historical performance of Alpa Laboratorie?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-alpa-laboratorie-3708676",
        "imagepath": "",
        "date": "2025-11-17 23:00:28",
        "description": "Answer:\nThe historical performance of Alpa Laboratorie shows a steady growth in net sales and profit over the years, with significant fluctuations in operating profit margins and expenses.\n\nBreakdown:\nAlpa Laboratorie's net sales increased from 85.97 Cr in Mar'20 to 112.45 Cr in Mar'25, with a notable rise from 92.44 Cr in Mar'23 to 108.74 Cr in Mar'24. The total operating income followed a similar trend, reaching 112.45 Cr in Mar'25. However, raw material costs have also risen significantly, from 49.48 Cr in Mar'21 to 70.72 Cr in Mar'25, contributing to total expenditure growth from 82.62 Cr in Mar'20 to 107.70 Cr in Mar'25. Operating profit (PBDIT) saw fluctuations, peaking at 10.69 Cr in Mar'22 before dropping to 4.75 Cr in Mar'25. Profit before tax increased from 2.54 Cr in Mar'19 to 25.67 Cr in Mar'25, while profit after tax rose from 0.93 Cr in Mar'19 to 19.50 Cr in Mar'25, indicating improved profita..."
      }
    ],
    "total": 83,
    "sid": "476646",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/alpa-laboratories-476646"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Consider And Approve The Financial Results For The Period Ended December 31 2025",
      "datetime": "29-Jan-2026",
      "details": "Alpa Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 inter alia to consider and approve the Unaudited Financial results of the Company for the Quarterly ended December 2025",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "25-Dec-2025",
      "details": "Alpa Laboratories has informed the exchange regarding the closure of trading window pursuant to SEBI (Prohibition of Insider Trading) Regulation 2015",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Board Meeting Intimation",
      "datetime": "04-Nov-2025",
      "details": "Alpa Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve ALPA LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 14-Nov-2025 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Alpa Laboratorie Sees Revision in Market Assessment Amid Challenging Financial Trends

2025-12-04 11:08:19

Alpa Laboratorie, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. Recent assessment changes highlight shifts across key performance parameters, signalling caution for investors amid subdued returns and operational difficulties.

Why is Alpa Laboratorie falling/rising?

2025-12-03 00:39:18

Recent Price Movement and Market Context Alpa Laboratories’ latest price action stands out in comparison to broader market trends. Over the past week, the stock has appreciated by 12.61%, substantially outperforming the Sensex’s modest 0.65% gain during the same period. This recent rally contrasts with the stock’s longer-term performance, which has been subdued; it has declined by 5.40% over the last month and remains down 27.94% year-to-date, while the Sensex has advanced 8.96% in the same timeframe. Despite these setbacks, the stock’s three- and five-year returns remain robust, with gains of 59.83% and 137.23% respectively, comfortably outpacing the Sensex’s 35.42% and 90.82% returns over those periods. The intraday trading on 02-Dec was marked by considerable volati...

Alpa Laboratories Stock Falls to 52-Week Low of Rs.76.25

2025-11-25 15:39:03

Alpa Laboratories has reached a new 52-week low, with its share price touching Rs.76.25 today. This marks a significant level for the pharmaceutical and biotechnology company amid a broader market environment where the Sensex is trading slightly lower.

Alpa Laboratories Stock Falls to 52-Week Low of Rs.78.01

2025-11-24 11:38:49

Alpa Laboratories has reached a new 52-week low of Rs.78.01, marking a significant decline amid broader market gains. The stock has underperformed its sector and key benchmarks, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology industry.

Alpa Laboratories Falls to 52-Week Low of Rs.78.02 Amidst Market Rally

2025-11-19 14:44:58

Alpa Laboratories, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.78.02 today, marking a significant decline amid a broadly positive market environment where the Sensex advanced by 0.64%.

Alpa Laboratories Faces Financial Challenges Amidst Strong Sales Growth and Market Struggles

2025-11-18 12:00:52

Alpa Laboratories has reported a challenging financial period for the quarter ending September 2025, with a decline in overall performance metrics. Despite a 21.86% increase in net sales to Rs 85.29 crore, profit after tax fell significantly. The company faces concerns regarding key performance indicators and market performance relative to the Sensex.

Alpa Laboratories Q2 FY26: Profit Plunges 98.57% as Operating Margins Turn Negative

2025-11-18 09:59:32

Alpa Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer, reported deeply troubling results for Q2 FY26, with consolidated net profit collapsing 98.57% year-on-year to just ₹0.11 crores from ₹7.69 crores in the same quarter last year. The catastrophic decline reflects severe operational distress as the company's operating margins turned sharply negative for the first time in recent years, raising serious questions about business viability. The stock, currently trading at ₹80.85 with a market capitalisation of ₹168.00 crores, has declined 28.70% over the past year, significantly underperforming both the benchmark Sensex and the pharmaceuticals sector.

Is Alpa Laboratorie overvalued or undervalued?

2025-11-18 08:20:36

As of 17 November 2025, the valuation grade for Alpa Laboratorie has moved from very attractive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE Ratio of 9.02, an EV to EBIT of -9.06, and an EV to EBITDA of -29.26, which suggest that the company's earnings and cash flows are under pressure. In comparison to its peers, Alpa Laboratorie shows a stark contrast with Sun Pharma, which has a PE Ratio of 36.69 and an EV to EBITDA of 24.22, and Cipla, with a PE Ratio of 22.81 and an EV to EBITDA of 16.14. These comparisons highlight that Alpa Laboratorie is lagging behind its industry counterparts in terms of valuation metrics. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -33.37% compared to the Sensex's 8.72%, reinforcing the notion of its overvaluation....

How has been the historical performance of Alpa Laboratorie?

2025-11-17 23:00:28

Answer: The historical performance of Alpa Laboratorie shows a steady growth in net sales and profit over the years, with significant fluctuations in operating profit margins and expenses. Breakdown: Alpa Laboratorie's net sales increased from 85.97 Cr in Mar'20 to 112.45 Cr in Mar'25, with a notable rise from 92.44 Cr in Mar'23 to 108.74 Cr in Mar'24. The total operating income followed a similar trend, reaching 112.45 Cr in Mar'25. However, raw material costs have also risen significantly, from 49.48 Cr in Mar'21 to 70.72 Cr in Mar'25, contributing to total expenditure growth from 82.62 Cr in Mar'20 to 107.70 Cr in Mar'25. Operating profit (PBDIT) saw fluctuations, peaking at 10.69 Cr in Mar'22 before dropping to 4.75 Cr in Mar'25. Profit before tax increased from 2.54 Cr in Mar'19 to 25.67 Cr in Mar'25, while profit after tax rose from 0.93 Cr in Mar'19 to 19.50 Cr in Mar'25, indicating improved profita...

View All News